Bayer’s Nubeqa drug won priority review status from the U.S. Food and Drug Administration, as the German drugmaker seeks to widen the use of the prostate cancer drug from an early disease stage to metastatic cases.
Novartis’ proposed drug for adults diagnosed with a certain type of advanced prostate cancer was given the green light for commercialization.
A therapy mix including Bayer’s Nubeqa drug was shown to significantly prolong the lives of men suffering from metastatic prostate cancer in a clinical study, prompting the company to boost sales estimates for the product.
A large U.S. study suggests college athletes who become infected with the coronavirus are very unlikely to have any lasting effects. Small studies have suggested that a common prostate cancer treatment might protect Covid-19 patients from becoming seriously ill.
Amgen is snapping up privately held Teneobio and the company’s class of biologics dubbed Human Heavy-Chain Antibodies in a deal that could total $2.5 billion.
In a roundup of scientific studies on the novel coronavirus and efforts to find treatments and vaccines, a prostate cancer drug improved Covid-19 survival in a clinical trial and mildly ill young Covid-19 patients reported lasting symptoms in another study.
Novartis AG received breakthrough therapy designation from the U.S. Food and Drug Administration for an experimental treatment for advanced castration-resistant prostate cancer, the Swiss drugmaker said on June 16.
As the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting presents many clinical trial updates, there appears to be a theme: access to drugs and pricing.
Bayer announced an agreement to acquire Noria Therapeutics Inc. and PSMA Therapeutics Inc. in an effort to expand the global biopharmaceutical company’s portfolio of targeted alpha radionuclide therapies for prostate cancer.
Men with a deadly form of advanced prostate cancer who failed other treatments survived four months longer after getting an experimental tumor-targeting radiation therapy from Swiss drugmaker Novartis, data released on June 3 showed.
